SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-19-105171
Filing Date
2019-04-12
Accepted
2019-04-12 16:11:03
Documents
3
Group Members
COLUMN GROUP GP, LPCOLUMN GROUP II GP, LPCOLUMN GROUP II, LPCOLUMN GROUP MANAGEMENT, LPDAVID V. GOEDDELPETER SVENNILSONPONOI CAPITAL II, LPPONOI CAPITAL, LPPONOI II MANAGEMENT, LLCPONOI MANAGEMENT, LLCTIM KUTZKEY

Document Format Files

Seq Description Document Type Size
1 SC 13D d679113dsc13d.htm SC 13D 216906
2 EX-99.A d679113dex99a.htm EX-99.A 13356
3 EX-99.E d679113dex99e.htm EX-99.E 6291
  Complete submission text file 0001193125-19-105171.txt   238399
Mailing Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158 415-865-2050
COLUMN GROUP L P (Filed by) CIK: 0001347769 (see all company filings)

IRS No.: 000000000
Type: SC 13D

Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Subject) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90978 | Film No.: 19746406
SIC: 2834 Pharmaceutical Preparations